(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 November 2022 (24.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/245739 A1

(51) International Patent Classification:
A61K 38/17 (2006.01) *A61P 27/02* (2006.01)

(21) International Application Number:
PCT/US2022/029462

(22) International Filing Date:
16 May 2022 (16.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/189,541	17 May 2021 (17.05.2021)	US
63/235,398	20 August 2021 (20.08.2021)	US
63/297,420	07 January 2022 (07.01.2022)	US
63/306,315	03 February 2022 (03.02.2022)	US

(71) Applicants: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BAYER HEALTHCARE LLC** [US/US]; 100 Bayer Boulevard, Whippany, New Jersey 07981 (US).

(72) Inventors: **VITTI, Robert L.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BERLINER, Alyson J.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **CHU, Karen**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ASMUS, Friedrich**; Eitel-Fritz-Str. 2, 14129 Berlin (DE). **DA SILVA LEAL, Sergio Casimiro**; In den Steinreben 6A, 4153 Reinach (CH).

(74) Agent: **TERMES, Lance A.**; Schwabe, Williamson & Wyatt PC, 1211 SW 5th Ave., Suite 1900, Portland, Oregon 97204 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: EXTENDED, HIGH DOSE VEGF ANTAGONIST REGIMENS FOR TREATMENT OF ANGIOGENIC EYE DISORDERS




FIG. 56

(57) Abstract: The present invention relates to treatment regimens characterized by high doses of aflibercept (*e.g.*, 8 mg) and extended intervals between doses (*e.g.*, 12 weeks) with improved visual and anatomic outcomes relative to treatment with lower doses such as 2 mg.

[Continued on next page]

WO 2022/245739 A1

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*